Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $227.7 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities rose 40.71% to $227.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $227.7 million, a 40.71% increase, with the full-year FY2024 number at $227.7 million, up 40.71% from a year prior.
  • Total Non-Current Liabilities was $227.7 million for Q4 2024 at Rhythm Pharmaceuticals, up from $166.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $227.7 million in Q4 2024 to a low of $80.5 million in Q2 2022.
  • A 3-year average of $143.1 million and a median of $140.9 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 57.03% in 2023, then grew 29.03% in 2024.
  • Rhythm Pharmaceuticals' Total Non-Current Liabilities stood at $116.9 million in 2022, then soared by 38.46% to $161.8 million in 2023, then soared by 40.71% to $227.7 million in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Total Non-Current Liabilities are $227.7 million (Q4 2024), $166.8 million (Q2 2024), and $162.5 million (Q1 2024).